We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than 80% of Omvoh responders from the VIVID-1 ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

The VIVID-1 and VIVID-2 clinical trials were conducted to evaluate its efficacy and safety in patients with moderately to severely active CD. VIVID-1, a phase 3 randomized controlled trial ...

On Friday, Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz). In January, the FDA approved Omvoh for moderately to severely ...

The findings were based on the VIVID-2 open-label extension study, which is evaluating the e?cacy and safety of Omvoh for up to three years in adults with moderately to severely active Crohn's ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.